Neurocrine Biosciences Presents Two-Year CRENESSITY Phase 3 Data at AACE 2026: 38% Glucocorticoid Dose Reduction in Classic CAH
Neurocrine Biosciences announced April 22 two-year data from the Phase 3 CAHtalyst Adult study at AACE 2026 in Las Vegas. CRENESSITY (crinecerfont), a CRF1 receptor antagonist that dampens the CRF-ACTH peptide signaling axis, achieved sustained glucocorticoid dose reductions in adults with classic congenital adrenal hyperplasia: mean daily GC dose decreased from 17.6 to 10.6 mg/m²/day HCe (−38%), and approximately 69% of patients achieved GC doses within the physiologic range while maintaining androgen control. No new safety signals emerged.